Janux Therapeutics (JANX) Change in Receivables (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Change in Receivables of $35.0 million for Q1 2026, up 401.36% quarter-over-quarter from $7.0 million in Q2 2024.
Powered by 
Analysis
Janux Therapeutics (JANX) Change in Receivables (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Change in Receivables for 6 consecutive years, with $35.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables changed N/A year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $42.0 million (up 459.75% YoY), while the FY2021 annual figure was -$8.0 million, down 200.0% from the prior year.
- Change in Receivables rose to $35.0 million in Q1 2026 per JANX's latest filing, from $7.0 million in the prior quarter.
- Across five years, Change in Receivables topped out at $35.0 million in Q1 2026 and bottomed at -$750000.0 in Q2 2023.
- Historically, Change in Receivables has averaged $6.1 million across 4 years, with a median of $519000.0 in 2024.
- On a YoY basis, Change in Receivables climbed as much as 1030.8% in 2024 and fell as far as 30.8% in 2024.
- Janux Therapeutics' Change in Receivables stood at -$500000.0 in 2022, then slumped by 50.0% to -$750000.0 in 2023, then soared by 1030.8% to $7.0 million in 2024, then jumped by 401.36% to $35.0 million in 2026.
- Business Quant data shows JANX's Change in Receivables at $35.0 million in Q1 2026, $7.0 million in Q2 2024, and $519000.0 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Janux Therapeutics | 1.27 Bn | 1.27 Bn | - | -34.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.85 Mn |
| Mar 31, 2026 | 35.00 Mn |
| Jun 30, 2024 | 6.98 Mn |
| Mar 31, 2024 | 519,000.00 |
| Jun 30, 2023 | -750,000.00 |
| Mar 31, 2023 | 750,000.00 |
| Dec 31, 2022 | -500,000.00 |
| Sep 30, 2022 | 500,000.00 |
| Sep 30, 2021 | -375,000.00 |
| Mar 31, 2021 | -7.63 Mn |
| Dec 31, 2020 | 8.00 Mn |